Treatment With Decitabine (DAC) After Azacitidine (AZA) Failure In High Risk Myelodysplastic Syndrome (MDS) and Advanced Chronic Myelomonocytic Leukemia (CMML)

被引：1
|
作者：
Braun, Thorsten
Cherait, Amina
Berthon, Celine
Willekens, Christophe
Park, Sophie
Rigal, Marthe
Brechignac, Sabine
Harel, Stephanie
Thepot, Sylvain
Quesnel, Bruno
Gardin, Claude
Ades, Lionel
Fenaux, Pierre
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
10.1182/blood.V122.21.2796.2796
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2796
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Results of 5-azacitidine therapy in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)
    Freyrie, A.
    Reda, G.
    Vincenti, D.
    Ferla, V.
    Orofino, N.
    Sciume, M.
    Guidotti, F.
    Cortelezzi, A.
    LEUKEMIA RESEARCH, 2013, 37 : S157 - S158
  • [22] Phase I study of volasertib combined with azacitidine in patients with previously untreated, high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) ineligible for high-intensity therapy
    Platzbecker, Uwe
    Scherres, Winrich
    Guo, Zhenchao
    Calvo, Roser
    Germing, Ulrich
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 : S233 - S233
  • [23] Decitabine induces responses in patients with myelodysplastic syndrome (MDS) after failure of azacitidine therapy.
    Borthakur, Gautam
    Ravandi-Kashani, Farhad
    Cortes, Jorge
    Jabbour, Elias
    Faderl, Stefan
    O'Brien, Susan
    Verstovsek, Srdan
    Garcia-Manero, Guillenno
    Newman, Beth Ann
    Giles, Francis
    Issa, Jean-Pierre
    Kantarjian, Hagop M.
    BLOOD, 2006, 108 (11) : 157A - 157A
  • [24] FLT3 mutations in myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)
    Bhamidipati, Pavan Kumar
    Daver, Naval Guastad
    Kantarjian, Hagop
    Pierce, Sherry
    Daver, Roshni
    Cortes, Jorge E.
    Ravandi, Farhad
    Mathisen, Michael
    Pemmaraju, Naveen
    Nazha, Aziz
    Kadia, Tapan M.
    Jabbour, Elias
    Borthakur, Gautam
    Faderl, Stefan
    Garcia-Manero, Guillermo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [25] RED BLOOD CELL (RBC) ALLOIMMUNIZATION AFTER BLOOD TRANSFUSION IN PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
    Nomdedeu, M.
    Sanz, C.
    Abello, D.
    Franquet, C.
    Cobo, F.
    Belkaid, M.
    Rozman, M.
    Aguilar, J. L.
    Nomdedeu, B.
    Pereira, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 132 - 132
  • [26] Development of Oral Azacitidine with Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms ( MPN) Including CMML (Chronic Myelomonocytic Leukemia) By Targeting Pharmacokinetic AUC Equivalence Vs Subcutaneous Azacitidine
    Garcia-Manero, Guillermo
    McCloskey, James
    Scott, Bart L.
    Griffiths, Elizabeth A.
    Kiner-Strachan, Bonnie
    Roboz, Gail J.
    Meyer, Janelle
    Chan, Winny
    Mirakhur, Beloo
    Sano, Yuri
    Oganesian, Aram
    Keer, Harold N.
    Savona, Michael R.
    BLOOD, 2023, 142
  • [27] Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)
    Hilton, C. Beau
    Sekeres, Mikkael A.
    Meggendorfer, Manja
    Walter, Wencke
    Hutter, Stephan
    Padron, Eric
    Savona, Michael R.
    Gerds, Aaron T.
    Guan, Yihong
    Sallman, David A.
    Mukherjee, Sudipto
    Patnaik, Mrinal M.
    Smith, Brianna
    Nagata, Yasunobu
    Adema, Vera
    Hasipek, Metis
    Hirsch, Cassandra M.
    Przychodzen, Bartlomiej P.
    Komrokji, Rami S.
    Jha, Babal K.
    Haferlach, Claudia
    Maciejewski, Jaroslaw P.
    Haferlach, Torsten
    Nazha, Aziz
    BLOOD, 2018, 132
  • [28] Development of Oral Azacitidine With Cedazuridine for Myelodysplastic Syndrome (MDS) and Myeloproliferative Neoplasms (MPN) Including Chronic Myelomonocytic Leukemia (CMML) by Targeting Pharmacokinetic AUC Equivalence vs Subcutaneous Azacitidine
    Garcia-Manero, Guillermo
    McCloskey, James
    Scott, Bart L.
    Griffiths, Elizabeth A.
    Kiner-Strachan, Bonnie
    Roboz, Gail J.
    Meyer, Janelle
    Chan, Winny
    Sano, Yuri
    Oganesian, Aram
    Keer, Harold K.
    Savona, Michael R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S406 - S407
  • [29] Topotecan A topoisomerase 1 inhibitor induces complete remissions in myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML).
    Beran, M
    OBrien, S
    Estey, E
    Keating, M
    Kantarjian, H
    BLOOD, 1996, 88 (10) : 2308 - 2308
  • [30] Decitabine induces high response rates in patients with chronic myelomonocytic leukemia (CMML).
    Jabbour, Elias
    O'Brien, Susan
    Ravandi-Kashani, Farhad
    Cortes, Jorge
    Borthakur, Gautam
    Verstovsek, Srdan
    Garcia-Manero, Guillermo
    Giles, Francis
    Zanoria, Lourdes
    Davisson, Jan
    Issa, Jean-Pierre
    Kantarjian, Hagop M.
    BLOOD, 2006, 108 (11) : 750A - 750A
12345